Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated a pediatric expansion of its…
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2…
Novavax Inc. (Nasdaq: NVAX) inked a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance (Gavi), to supply up to 1.1 billion cumulative doses of…
Military and connected beneficiaries of Fort Bragg’s Military Health System and Tricare can lend a hand to help the biomedical research necessary to get another…
Affiliated with Brown University, Rhode Island Hospitals and Health Services also known as Lifespan now seeks to enroll volunteers for the Phase 3 Novavax COVID-19…
One of the first physician/investigators to distribute the Novavax vaccine in the recently launched Phase 3 clinical trial was showcased via Utah’s KUTV recently as…
Led by Principal Investigator Dr. Scott McClelland and Dr. Anna Wald, the University of Washington School of Medicine (UW Medicine) kicks off the Phase 3…
The University of Iowa Health Care (UIHC) gains a more prominent role as a trial site hub investigating COVID-19 investigational vaccines now taking on leadership…
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. NVX‑CoV2373 is…
What does a niche vaccine-focused biotech from Gaithersburg, MD toiling in relative obscurity for years and a small Native American nation in the far Pacific…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
